Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Harrow, Inc. HROW

Healthcare  —  Drug Manufacturers Specialty & Generic
33.07 (0.03) (0.09%) as of 25 Sep
Market cap
$1.2B
P/E
0.0×
Revenue Champion (5y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Harrow, Inc. (HROW) Business Profile

Updated before January 2025

Company Overview

Harrow, Inc. (HROW) is a leading pharmaceutical company specializing in the development, manufacturing, and commercialization of innovative ophthalmic products. Founded in 2012 and headquartered in Nashville, Tennessee, Harrow has established itself as a key player in the eye care industry. The company was founded with the mission of improving patient outcomes by providing high-quality, affordable medications and services tailored to the needs of ophthalmologists and optometrists.

Harrow’s leadership team is composed of seasoned professionals with extensive experience in the pharmaceutical and healthcare sectors. Mark L. Baum, the company’s CEO, has been instrumental in driving Harrow’s growth and strategic direction. Under his leadership, Harrow has expanded its product portfolio, strengthened its market presence, and built a reputation for innovation and customer-centric solutions.

Core Business Segments

Harrow operates through several core business segments, each focused on addressing specific needs within the ophthalmic market. These segments include:

Compounded Pharmaceuticals

Harrow is a leader in the compounding of ophthalmic medications. The company provides customized formulations that address unique patient needs, offering solutions that are not readily available through traditional pharmaceutical channels. Key products in this category include:

  • Dropless Therapy®: A line of injectable medications designed to reduce or eliminate the need for post-operative eye drops following cataract surgery.
  • LessDrops®: A suite of compounded eye drop formulations that combine multiple active ingredients to simplify dosing regimens for patients.

Branded Pharmaceuticals

Harrow has also developed a portfolio of branded ophthalmic products that address common eye conditions such as dry eye, glaucoma, and inflammation. These products are designed to provide effective, convenient, and affordable treatment options for patients.

Pharmaceutical Services

In addition to its product offerings, Harrow provides a range of services to support ophthalmologists and optometrists. These services include:

  • Pharmacy Services: Through its wholly-owned subsidiary, ImprimisRx, Harrow operates a network of compounding pharmacies that serve eye care professionals across the United States.
  • Clinical Support: Harrow offers educational resources and clinical support to help healthcare providers optimize patient care.

Business Model

Harrow’s business model is centered around the integration of products and services to create a comprehensive solution for eye care professionals. The company generates revenue through the sale of compounded and branded pharmaceuticals, as well as through its pharmacy and clinical support services. By focusing on innovation, quality, and affordability, Harrow has built a loyal customer base and established itself as a trusted partner in the ophthalmic community.

Harrow’s vertically integrated approach allows it to control every aspect of the product lifecycle, from research and development to manufacturing and distribution. This not only ensures the highest standards of quality but also enables the company to respond quickly to market demands and regulatory changes.

Strategic Direction

Harrow is committed to driving growth and innovation in the ophthalmic market. The company’s strategic priorities include:

  • Expanding Product Portfolio: Harrow is actively investing in research and development to bring new and improved ophthalmic products to market. The company is particularly focused on addressing unmet medical needs and enhancing patient outcomes.
  • Geographic Expansion: Harrow aims to extend its reach beyond the United States by entering new international markets. This will enable the company to serve a broader patient population and diversify its revenue streams.
  • Sustainability Goals: Harrow is dedicated to minimizing its environmental impact by adopting sustainable practices across its operations. This includes reducing waste, optimizing energy use, and sourcing materials responsibly.
  • Digital Transformation: Harrow is leveraging technology to enhance its operations and customer experience. This includes the development of digital tools and platforms to streamline workflows and improve access to its products and services.

Competitive Landscape

Harrow operates in a highly competitive market, facing competition from both large pharmaceutical companies and smaller niche players. Key competitors include:

  • Allergan (a subsidiary of AbbVie): A global leader in eye care products, including treatments for glaucoma, dry eye, and retinal diseases.
  • Alcon: A leading provider of surgical and vision care products, with a strong presence in the ophthalmic market.
  • Bausch + Lomb: A well-established company offering a wide range of eye care products, including contact lenses, pharmaceuticals, and surgical devices.
  • Smaller Compounding Pharmacies: Harrow also competes with regional and local compounding pharmacies that offer customized ophthalmic formulations.

Despite the competitive landscape, Harrow has carved out a niche for itself by focusing on innovation, affordability, and customer service.

Risk Factors

Like any business, Harrow faces several risks that could impact its performance. Key risk factors include:

  • Regulatory Challenges: The pharmaceutical industry is heavily regulated, and changes in laws or regulations could affect Harrow’s operations and product offerings.
  • Market Dependence: Harrow’s success is closely tied to the ophthalmic market, making it vulnerable to fluctuations in demand or changes in treatment protocols.
  • Supply Chain Disruptions: Any disruptions in the supply chain, such as shortages of raw materials or manufacturing delays, could impact Harrow’s ability to deliver products to customers.
  • Competition: Intense competition from both established players and new entrants could pressure Harrow’s market share and profitability.

Recent Developments

Harrow has made significant strides in recent years, including:

  • New Product Launches: The company has introduced several new ophthalmic products, further strengthening its portfolio and addressing unmet medical needs.
  • Strategic Partnerships: Harrow has entered into partnerships with other pharmaceutical companies and healthcare organizations to expand its reach and capabilities.
  • Operational Improvements: Harrow has invested in upgrading its manufacturing facilities and supply chain infrastructure to enhance efficiency and scalability.
  • Response to Global Events: The company has adapted to challenges posed by the COVID-19 pandemic, ensuring the continuity of its operations and the availability of its products.

Investment Considerations

Harrow offers several strengths and risks for potential investors to consider:

Strengths

  • Strong Market Position: Harrow is a leader in the ophthalmic market, with a well-established brand and loyal customer base.
  • Innovative Products: The company’s focus on innovation has resulted in a robust portfolio of high-quality, affordable medications.
  • Growth Potential: Harrow’s strategic initiatives, including geographic expansion and new product development, position it for long-term growth.

Risks

  • Regulatory and Market Risks: Changes in regulations or market dynamics could impact Harrow’s performance.
  • Competitive Pressure: Intense competition could affect the company’s market share and profitability.
  • Operational Risks: Supply chain disruptions or manufacturing issues could impact Harrow’s ability to meet customer demand.

Conclusion

Harrow, Inc. is a dynamic and innovative company that has established itself as a leader in the ophthalmic market. With a strong product portfolio, a customer-centric approach, and a commitment to growth and sustainability, Harrow is well-positioned for future success. While the company faces certain risks, its strengths and strategic initiatives make it an attractive option for investors seeking exposure to the healthcare sector.